U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07735533) titled 'A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies' on July 24.
Brief Summary: This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Lymphoma, B Cell
Lymphoma Non-Hodgkin
High Grade B Cell Lymphoma
Richter Transformation Lymphoma
Grade 3b Follicular Lymphoma
Primary Mediastinal B Cell Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL)
Intervent...